Taiwan
· Delayed Price · Currency is TWD Mercury Biopharmaceutical Statistics
Total Valuation
Mercury Biopharmaceutical has a market cap or net worth of TWD 5.51 billion. The enterprise value is 5.29 billion.
| Market Cap | 5.51B |
| Enterprise Value | 5.29B |
Important Dates
The last earnings date was Wednesday, November 13, 2024.
| Earnings Date | Nov 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Mercury Biopharmaceutical has 417.45 million shares outstanding. The number of shares has increased by 3.20% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 417.45M |
| Shares Change (YoY) | +3.20% |
| Shares Change (QoQ) | -0.08% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.04% |
| Float | 393.16M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 16.89 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -121.79 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -130.36 |
Financial Position
The company has a current ratio of 20.57, with a Debt / Equity ratio of 0.13.
| Current Ratio | 20.57 |
| Quick Ratio | 20.07 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.03 |
| Interest Coverage | -63.42 |
Financial Efficiency
Return on equity (ROE) is -11.79% and return on invested capital (ROIC) is -7.12%.
| Return on Equity (ROE) | -11.79% |
| Return on Assets (ROA) | -6.98% |
| Return on Capital (ROIC) | -7.12% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -33.92% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -33.92% |
| 50-Day Moving Average | 14.90 |
| 200-Day Moving Average | 15.46 |
| Relative Strength Index (RSI) | 28.56 |
| Average Volume (20 Days) | 271,397 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Mercury Biopharmaceutical had revenue of TWD 5.75 million and -43.41 million in losses. Loss per share was -0.10.
| Revenue | 5.75M |
| Gross Profit | 4.57M |
| Operating Income | -46.80M |
| Pretax Income | -43.39M |
| Net Income | -43.41M |
| EBITDA | -42.29M |
| EBIT | -46.80M |
| Loss Per Share | -0.10 |
Balance Sheet
The company has 264.89 million in cash and 41.95 million in debt, giving a net cash position of 222.94 million or 0.53 per share.
| Cash & Cash Equivalents | 264.89M |
| Total Debt | 41.95M |
| Net Cash | 222.94M |
| Net Cash Per Share | 0.53 |
| Equity (Book Value) | 323.91M |
| Book Value Per Share | 0.78 |
| Working Capital | 262.12M |
Cash Flow
In the last 12 months, operating cash flow was -28.70 million and capital expenditures -11.86 million, giving a free cash flow of -40.56 million.
| Operating Cash Flow | -28.70M |
| Capital Expenditures | -11.86M |
| Free Cash Flow | -40.56M |
| FCF Per Share | -0.10 |
Margins
| Gross Margin | 79.44% |
| Operating Margin | -813.97% |
| Pretax Margin | -754.57% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -705.41% |
Dividends & Yields
Mercury Biopharmaceutical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.20% |
| Shareholder Yield | -3.20% |
| Earnings Yield | -0.79% |
| FCF Yield | -0.74% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Mercury Biopharmaceutical has an Altman Z-Score of 84.23.
| Altman Z-Score | 84.23 |
| Piotroski F-Score | n/a |